Anebulo Pharmaceuticals, Inc. (ANEB)

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates.

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates.

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the “Company” or “Anebulo”), today announces the first subjects dosed in its Phase 1 single ascending dose (“SAD”) study of intravenous (IV) selonabant in healthy young adults. The study is supported by a collaborative grant from the National Institute on Drug Abuse (NIDA). First Subjec.

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that a Special Committee of independent directors has recommended, and its Board of Directors (the “Board”) has approved, as part of a going private transaction, a reverse stock split at a ratio of not less than 1-for-2,500 and not greater than.

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended March 31, 2025, and recent updates. Third Quarter Fiscal Year 2025 and Subsequent Highlights: Anebulo is prioritizing the advancement of an intravenous selonabant as a potential treatment for pediatri.

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2024, and recent updates. Second Quarter Fiscal Year 2025 and Subsequent Highlights: In December 2024, Anebulo met with FDA to discuss the development of intravenous selonabant and the in.

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise.

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates.

BOSTON--(BUSINESS WIRE)--Galehead Development, LLC (“Galehead”) and Rivian Automotive, LLC (“Rivian”) have entered into an agreement to collaborate on the development of renewable energy resources tailored to Rivian's locational and environmental priorities. Galehead will develop solar projects with specific consideration for Rivian's “3C” Framework. The 3C Framework is a progressive procurement standard that commits Rivian to sourcing renewable energy from projects that have a measurable posit.

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid toxicities that include acute cannabinoid intoxication (ACI) and unintentional cannabis poisoning (the “Company” or “Anebulo”), today announced financial results for the three months ended March 31, 2024, and recent updates. Third Quarter Fiscal Year 2024 and Subsequent Highlights: Anebulo prioritizes deve.

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates.

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates.

Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Conmed (CNMD) have performed compared to their sector so far this year.

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) ("Anebulo"), today announced the appointment of Bimal Shah to its Board of Directors. Mr. Shah will serve as a member of the board's audit and compensation committees. "I am pleased to welcome Bimal to the Anebulo Board," said Dr. Joseph Lawler, Anebulo's Chairman. "Bimal's depth of fina.

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces New CEO.

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three and twelve months ended June 30, 2023, and recent updates. Fourth Quarter Fiscal Year 2023 and Subsequent Highlights: Positive feedback from the Type B meeting with the FDA supports advancin.